222 South Ninth Street
Minneapolis, MN 55402
www.Oppenheimer.com
|
Direct: |
(612) 607-7287 |
|
Main: |
(612) 607-7000 |
|
Fax: |
(612) 607-7100 |
|
E-Mail: |
ACulbert@oppenheimer.com |
October 31, 2012
VIA FACSIMILE AND EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
|
Attn: |
Mr. Jeffrey Riedler |
|
|
Assistant Director |
|
|
Mail Stop 4720 |
|
Re: |
BioSante Pharmaceuticals, Inc. |
|
|
Form 10-K for the fiscal year ended December 31, 2011 |
|
|
Filed March 13, 2012 |
|
|
File No. 001-31812 |
Dear Mr. Riedler:
The purpose of this letter is to respectfully request in writing an extension to the time period to respond to the comment letter, dated October 18, 2012, to Mr. Phillip B. Donenberg, Senior Vice President of Finance, Chief Financial Officer and Secretary of BioSante Pharmaceuticals, Inc., regarding BioSante’s annual report on Form 10-K for the fiscal year ended December 31, 2011 filed with the Securities and Exchange Commission on March 13, 2012. As communicated in a telephone conversation between Deanna Counsell of our Firm and you, BioSante respectfully requests an extension to file its response to the October 18, 2012 comment letter not later than November 8, 2012.
If you have any questions, please do not hesitate to contact me at (612) 607-7287. We greatly appreciate your attention to this matter.
|
Very truly yours, |
|
|
|
|
|
/s/ Amy E. Culbert |
|
|
|
|
|
Amy E. Culbert |
|
|
cc: |
Johnny Gharib, Division of Corporation Finance, Securities and Exchange Commission |
|
|
John Krug, Division of Corporation Finance, Securities and Exchange Commission |
|
|
Stephen M. Simes, BioSante Pharmaceuticals, Inc. |
|
|
Phillip B. Donenberg, BioSante Pharmaceuticals, Inc. |
|
|
Michael Lullo, Deloitte & Touche LLP |